Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://quickbooksspecialist.com
Are you over 18 and want to see adult content?
A complete backup of https://kyfb.com
Are you over 18 and want to see adult content?
A complete backup of https://svgator.com
Are you over 18 and want to see adult content?
A complete backup of https://photodon.com
Are you over 18 and want to see adult content?
A complete backup of https://sharkstewards.org
Are you over 18 and want to see adult content?
A complete backup of https://ippen-digital.de
Are you over 18 and want to see adult content?
A complete backup of https://reynaers.be
Are you over 18 and want to see adult content?
A complete backup of https://topsearch.gr
Are you over 18 and want to see adult content?
A complete backup of https://skiplan.com
Are you over 18 and want to see adult content?
A complete backup of https://tslprb.in
Are you over 18 and want to see adult content?
A complete backup of https://adamseve.com
Are you over 18 and want to see adult content?
A complete backup of https://pftcasting.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.gloryholeswallow.com
Are you over 18 and want to see adult content?
A complete backup of www.amateuralbum.net
Are you over 18 and want to see adult content?
A complete backup of www.planetsuzy.org
Are you over 18 and want to see adult content?
A complete backup of www.quartier-rouge.be
Are you over 18 and want to see adult content?
A complete backup of www.overthedesk.com
Are you over 18 and want to see adult content?
A complete backup of www.coedcherry.com
Are you over 18 and want to see adult content?
Text
MANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. CHRONIC LYMPHOCYTIC LEUKEMIA: FROM MOLECULAR PATHOGENESIS haematologica | 2020; 105(9) 2205 Received: April 29, 2020. Accepted: June 18, 2020. Pre-published: July 2, 2020. ©2020 Ferrata StortiFoundation
PERSISTENCE OF MYELOFIBROSIS TREATED WITH RUXOLITINIB Activation of JAK-STAT signaling is one of the hallmarks of myelofibrosis, a myeloproliferative neoplasm that leads to inflammation, progressive bone marrow failure, and a risk of leukemic transformation. Around 90% of patients with myelofibrosis have a mutation in JAK2, MPL, or CALR: so-called ‘driver’ mutations that lead to activation of JAK2. CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
NORMAL AND PATHOLOGICAL ERYTHROPOIESIS IN ADULTS: FROMSEE MORE ONHAEMATOLOGICA.ORG23
CHRONIC LYMPHOCYTIC LEUKAEMIA AND Figure 1. Morphology and phenotype at diagnosis and through the follow up of the patient. In flow cytometry images, B-cell prolymphocytic leukemia (B-PLL) is shown in light blue, chronic lymphocytic leukaemia (CLL) in red and polytypic B lymphocytes in black. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. CHRONIC LYMPHOCYTIC LEUKEMIA: FROM MOLECULAR PATHOGENESIS haematologica | 2020; 105(9) 2205 Received: April 29, 2020. Accepted: June 18, 2020. Pre-published: July 2, 2020. ©2020 Ferrata StortiFoundation
PERSISTENCE OF MYELOFIBROSIS TREATED WITH RUXOLITINIB Activation of JAK-STAT signaling is one of the hallmarks of myelofibrosis, a myeloproliferative neoplasm that leads to inflammation, progressive bone marrow failure, and a risk of leukemic transformation. Around 90% of patients with myelofibrosis have a mutation in JAK2, MPL, or CALR: so-called ‘driver’ mutations that lead to activation of JAK2. CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
NORMAL AND PATHOLOGICAL ERYTHROPOIESIS IN ADULTS: FROMSEE MORE ONHAEMATOLOGICA.ORG23
CHRONIC LYMPHOCYTIC LEUKAEMIA AND Figure 1. Morphology and phenotype at diagnosis and through the follow up of the patient. In flow cytometry images, B-cell prolymphocytic leukemia (B-PLL) is shown in light blue, chronic lymphocytic leukaemia (CLL) in red and polytypic B lymphocytes in black. EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance. ARCHIVES | HAEMATOLOGICA We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. DASATINIB AND ALLOGENEIC STEM CELL TRANSPLANTATION ENABLE Figure 2. Dasatinib causes a decrease of RCSD1-ABL1-positive cells and leads, in combination with allo-SCT, to long-term remission.A. May-Grünwald-Giemsa staining of patient’s bone marrow smears from 07/2013 before (left panels) and after (right panels) 16 d dasatinibtreatment.
FAMILY-DIRECTED UMBILICAL CORD BLOOD BANKING Umbilical cord blood transplantation from HLA-identical siblings provides good results in children. These results support targeted efforts to bank family cord blood units that can be used for a sibling diagnosed with a disease which can be cured by allogeneic hematopoietic stem cell transplantation or for research that investigates the use of allogeneic or autologous cord blood cells. PATHOGENESIS, ETIOLOGY AND EPIDEMIOLOGY OF MYELODYSPLASTIC BACKGROUND AND OBJECTIVE: The myelodysplastic syndromes are common hematological malignancies affecting predominantly elderly people. Patients usually present with chronic cytopenias which gradually worsen due to progressive bone marrow failure or transformation into acute myeloid leukemia. Disease prevention is more cost-effective than therapeutic intervention and the HEMATOPOIETIC STEM CELL TRANSPLANTATION: 40 YEARS OF Open access journal of the Ferrata-Storti Foundation, a no profit organization Vol. 93 No. 11 (2008): November, 2008 Hematopoietic stem cell transplantation: 40 years of THE COMPLEX KARYOTYPE LANDSCAPE IN CHRONIC LYMPHOCYTIC The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation by Andrea Visentin, Laura Bonaldi, THALIDOMIDE INDUCED REMISSION OF REFRACTORY DIFFUSE LARGE Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation. CHROMOSOME 1Q21 ABNORMALITIES REFINE OUTCOME PREDICTION IN 1 Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients Niels Weinhold 1, Hans J. Salwender2, David A Cairns3, Marc S. Raab, George Waldron4, Igor W Blau5, Uta Bertsch1, Thomas Hielscher6, Gareth J Morgan7, Anna Jauch8, Faith E Davies7, Mathias Hänel9, Gordon Cook10, Christoph Scheid11, Richard Houlston4, Hartmut TIME TO RECONSIDER CD33 SNP FOR GEMTUZUMAB RESPONSE Time to reconsider CD33 SNP for Gemtuzumab response Jatinder K Lamba1 and Soheil Meshinchi2 1Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, UF Health Cancer Center, University of Florida, Gainesville, FL; 2Division of Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
One of the ALDH family genes, ALDH1A2, is aberrantly expressed in more than 50% of cases of T-cell acute lymphoblastic leukemia. This study revealed that ALDH1A2 protects against intracellular stress and promotes T-ALL cell metabolism and survival. VOL. 106 NO. 6 (2021): JUNE, 2021 Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP (506 Online Views) Ron Daniel Jachimowicz, Luise Pieper, Sarah Reinke, Artur Gontarewicz, Annette Plütschow, Heinz Haverkamp, Leonie Frauenfeld, Falko Fend, Mathis Overkamp, Franziska Jochims HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
What about you? Tell us your interest and get all the new contents of haematologica in advance. CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization PERIPHERAL NEUROPATHY AND MONOCLONAL GAMMOPATHY OF Monoclonal gammopathy of undetermined significance (MGUS) is a common benign precursor condition of multiple myeloma (MM) and related disorders. 1, 2 MGUS is considered asymptomatic but has been shown to be associated with peripheral neuropathy (PN). 3 However, the literature is unclear regarding the prevalence, clinical implications, and even the existence of MGUS-associated PN. 4 We VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization GEMTUZUMAB OZOGAMICIN FOR DE NOVO ACUTE MYELOID LEUKEMIASEE MORE ONHAEMATOLOGICA.ORG
SAFETY AND EFFICACY OF DARATUMUMAB IN DIALYSIS-DEPENDENT Immunotherapy has now been established as a new treatment paradigm for multiple myeloma (MM), due to its ability to induce deep and durable responses, even in patients refractory to multiple classes of novel agents, without adding the cost of relevant toxicities. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
One of the ALDH family genes, ALDH1A2, is aberrantly expressed in more than 50% of cases of T-cell acute lymphoblastic leukemia. This study revealed that ALDH1A2 protects against intracellular stress and promotes T-ALL cell metabolism and survival. VOL. 106 NO. 6 (2021): JUNE, 2021 Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP (506 Online Views) Ron Daniel Jachimowicz, Luise Pieper, Sarah Reinke, Artur Gontarewicz, Annette Plütschow, Heinz Haverkamp, Leonie Frauenfeld, Falko Fend, Mathis Overkamp, Franziska Jochims HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
What about you? Tell us your interest and get all the new contents of haematologica in advance. CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization PERIPHERAL NEUROPATHY AND MONOCLONAL GAMMOPATHY OF Monoclonal gammopathy of undetermined significance (MGUS) is a common benign precursor condition of multiple myeloma (MM) and related disorders. 1, 2 MGUS is considered asymptomatic but has been shown to be associated with peripheral neuropathy (PN). 3 However, the literature is unclear regarding the prevalence, clinical implications, and even the existence of MGUS-associated PN. 4 We VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization GEMTUZUMAB OZOGAMICIN FOR DE NOVO ACUTE MYELOID LEUKEMIASEE MORE ONHAEMATOLOGICA.ORG
SAFETY AND EFFICACY OF DARATUMUMAB IN DIALYSIS-DEPENDENT Immunotherapy has now been established as a new treatment paradigm for multiple myeloma (MM), due to its ability to induce deep and durable responses, even in patients refractory to multiple classes of novel agents, without adding the cost of relevant toxicities. DASATINIB AND ALLOGENEIC STEM CELL TRANSPLANTATION ENABLE Figure 2. Dasatinib causes a decrease of RCSD1-ABL1-positive cells and leads, in combination with allo-SCT, to long-term remission.A. May-Grünwald-Giemsa staining of patient’s bone marrow smears from 07/2013 before (left panels) and after (right panels) 16 d dasatinibtreatment.
FAMILY-DIRECTED UMBILICAL CORD BLOOD BANKING Umbilical cord blood transplantation from HLA-identical siblings provides good results in children. These results support targeted efforts to bank family cord blood units that can be used for a sibling diagnosed with a disease which can be cured by allogeneic hematopoietic stem cell transplantation or for research that investigates the use of allogeneic or autologous cord blood cells. PATHOGENESIS, ETIOLOGY AND EPIDEMIOLOGY OF MYELODYSPLASTIC BACKGROUND AND OBJECTIVE: The myelodysplastic syndromes are common hematological malignancies affecting predominantly elderly people. Patients usually present with chronic cytopenias which gradually worsen due to progressive bone marrow failure or transformation into acute myeloid leukemia. Disease prevention is more cost-effective than therapeutic intervention and the ARCHIVES | HAEMATOLOGICA We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. HEMATOPOIETIC STEM CELL TRANSPLANTATION: 40 YEARS OF Open access journal of the Ferrata-Storti Foundation, a no profit organization Vol. 93 No. 11 (2008): November, 2008 Hematopoietic stem cell transplantation: 40 years ofCASE REPORTS
642 haematologica | 2021; 106(2) Case Reports Figure 1. Clinical, brain magnetic resonance imaging (MRI) and chest computed tomography (CT) images of tubercolosis (TB) and fungal infections, and THALIDOMIDE INDUCED REMISSION OF REFRACTORY DIFFUSE LARGE Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation. CHROMOSOME 1Q21 ABNORMALITIES REFINE OUTCOME PREDICTION IN 1 Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients Niels Weinhold 1, Hans J. Salwender2, David A Cairns3, Marc S. Raab, George Waldron4, Igor W Blau5, Uta Bertsch1, Thomas Hielscher6, Gareth J Morgan7, Anna Jauch8, Faith E Davies7, Mathias Hänel9, Gordon Cook10, Christoph Scheid11, Richard Houlston4, Hartmut THE COMPLEX KARYOTYPE LANDSCAPE IN CHRONIC LYMPHOCYTIC The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation by Andrea Visentin, Laura Bonaldi, TIME TO RECONSIDER CD33 SNP FOR GEMTUZUMAB RESPONSE Time to reconsider CD33 SNP for Gemtuzumab response Jatinder K Lamba1 and Soheil Meshinchi2 1Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, UF Health Cancer Center, University of Florida, Gainesville, FL; 2Division of Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. EARLY VIEW | HAEMATOLOGICA1 The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance. CHRONIC LYMPHOCYTIC LEUKEMIA: FROM MOLECULAR PATHOGENESIS haematologica | 2020; 105(9) 2205 Received: April 29, 2020. Accepted: June 18, 2020. Pre-published: July 2, 2020. ©2020 Ferrata StortiFoundation
VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
SAFETY AND EFFICACY OF DARATUMUMAB IN DIALYSIS-DEPENDENT Immunotherapy has now been established as a new treatment paradigm for multiple myeloma (MM), due to its ability to induce deep and durable responses, even in patients refractory to multiple classes of novel agents, without adding the cost of relevant toxicities. SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND 5 Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of thetranscriptional
HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. EARLY VIEW | HAEMATOLOGICA1 The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance. CHRONIC LYMPHOCYTIC LEUKEMIA: FROM MOLECULAR PATHOGENESIS haematologica | 2020; 105(9) 2205 Received: April 29, 2020. Accepted: June 18, 2020. Pre-published: July 2, 2020. ©2020 Ferrata StortiFoundation
VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
SAFETY AND EFFICACY OF DARATUMUMAB IN DIALYSIS-DEPENDENT Immunotherapy has now been established as a new treatment paradigm for multiple myeloma (MM), due to its ability to induce deep and durable responses, even in patients refractory to multiple classes of novel agents, without adding the cost of relevant toxicities. SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND 5 Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of thetranscriptional
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance. DASATINIB AND ALLOGENEIC STEM CELL TRANSPLANTATION ENABLE Figure 2. Dasatinib causes a decrease of RCSD1-ABL1-positive cells and leads, in combination with allo-SCT, to long-term remission.A. May-Grünwald-Giemsa staining of patient’s bone marrow smears from 07/2013 before (left panels) and after (right panels) 16 d dasatinibtreatment.
PATHOGENESIS, ETIOLOGY AND EPIDEMIOLOGY OF MYELODYSPLASTIC BACKGROUND AND OBJECTIVE: The myelodysplastic syndromes are common hematological malignancies affecting predominantly elderly people. Patients usually present with chronic cytopenias which gradually worsen due to progressive bone marrow failure or transformation into acute myeloid leukemia. Disease prevention is more cost-effective than therapeutic intervention and the FAMILY-DIRECTED UMBILICAL CORD BLOOD BANKING Umbilical cord blood transplantation from HLA-identical siblings provides good results in children. These results support targeted efforts to bank family cord blood units that can be used for a sibling diagnosed with a disease which can be cured by allogeneic hematopoietic stem cell transplantation or for research that investigates the use of allogeneic or autologous cord blood cells. HEMATOPOIETIC STEM CELL TRANSPLANTATION: 40 YEARS OF Fulvio Porta, Franco Locatelli, Giuseppe Roberto Burgio. Hematopoietic stem cell transplantation: 40 years of continuous progress andevolution.
THE COMPLEX KARYOTYPE LANDSCAPE IN CHRONIC LYMPHOCYTIC The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation by Andrea Visentin, Laura Bonaldi, THALIDOMIDE INDUCED REMISSION OF REFRACTORY DIFFUSE LARGE Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation. CHROMOSOME 1Q21 ABNORMALITIES REFINE OUTCOME PREDICTION IN 1 Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients Niels Weinhold 1, Hans J. Salwender2, David A Cairns3, Marc S. Raab, George Waldron4, Igor W Blau5, Uta Bertsch1, Thomas Hielscher6, Gareth J Morgan7, Anna Jauch8, Faith E Davies7, Mathias Hänel9, Gordon Cook10, Christoph Scheid11, Richard Houlston4, Hartmut TIME TO RECONSIDER CD33 SNP FOR GEMTUZUMAB RESPONSE Time to reconsider CD33 SNP for Gemtuzumab response Jatinder K Lamba1 and Soheil Meshinchi2 1Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, UF Health Cancer Center, University of Florida, Gainesville, FL; 2Division of Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
EARLY VIEW | HAEMATOLOGICA The COVID-19 pandemic has resulted in significant morbidity and mortality worldwide. To prevent severe infection, mass COVID-19 vaccination campaigns with several vaccine types are currently underway. We report pathological and immunological findings in 8 patients who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after administration of SARS-CoV-2 vaccine HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden IN SEARCH OF THE OPTIMAL PROTEOSOME INHIBITOR. HOW, WHEN 1 In search of the optimal proteosome inhibitor. How, when and for whom? Monika Engelhardt1, Sara Bringhen2, Philippe Moreau3, Ralph Wäsch1, Johannes Waldschmidt1 1 University of Freiburg, Hematology & Oncology, Faculty of Freiburg, Hugstetterstr. 53, 79106 Freiburg 2 Myeloma Unit, Division of Hematology, University of Turino, Azienda Ospedaliero-Universitaria Citta della Salute e THE TMPRSS6 VARIANT (SNP RS855791) AFFECTS IRON METABOLISM1 1 The TMPRSS6 variant (SNP rs855791) affects iron metabolism and oral iron absorption – a stable iron isotope study in Taiwanese women Simone Buerkli,1 Sung-Nan Pei,2,3,4 Shu-Chen Hsiao,5 Chien-Te Lee2, Christophe Zeder,1 Michael B. Zimmermann,1 Diego Moretti1,6 1Laboratory of Human Nutrition, Institute of Food Nutrition and Health, Department of EUROPEAN MYELOMA NETWORK PERSPECTIVE ON CAR T-CELL1 European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma by Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, Francesca Gay, Luisa Giaccone, ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
CENTRAL NERVOUS SYSTEM PROPHYLAXIS IN DIFFUSE LARGE B-CELL and/or BCL6 rearrangements (HGBCL-DH/TH).13 Indeed, Bobillo et al. observed that patients with ABC (non-GCB) DLBCL subtype had an overall higher risk of CNS relapse in their series.1Furthermore, recent multiplatform genom- ic profiling studies have identified geneticsubtypes of
HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
EARLY VIEW | HAEMATOLOGICA The COVID-19 pandemic has resulted in significant morbidity and mortality worldwide. To prevent severe infection, mass COVID-19 vaccination campaigns with several vaccine types are currently underway. We report pathological and immunological findings in 8 patients who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after administration of SARS-CoV-2 vaccine HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden IN SEARCH OF THE OPTIMAL PROTEOSOME INHIBITOR. HOW, WHEN 1 In search of the optimal proteosome inhibitor. How, when and for whom? Monika Engelhardt1, Sara Bringhen2, Philippe Moreau3, Ralph Wäsch1, Johannes Waldschmidt1 1 University of Freiburg, Hematology & Oncology, Faculty of Freiburg, Hugstetterstr. 53, 79106 Freiburg 2 Myeloma Unit, Division of Hematology, University of Turino, Azienda Ospedaliero-Universitaria Citta della Salute e THE TMPRSS6 VARIANT (SNP RS855791) AFFECTS IRON METABOLISM1 1 The TMPRSS6 variant (SNP rs855791) affects iron metabolism and oral iron absorption – a stable iron isotope study in Taiwanese women Simone Buerkli,1 Sung-Nan Pei,2,3,4 Shu-Chen Hsiao,5 Chien-Te Lee2, Christophe Zeder,1 Michael B. Zimmermann,1 Diego Moretti1,6 1Laboratory of Human Nutrition, Institute of Food Nutrition and Health, Department of EUROPEAN MYELOMA NETWORK PERSPECTIVE ON CAR T-CELL1 European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma by Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, Francesca Gay, Luisa Giaccone, ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
CENTRAL NERVOUS SYSTEM PROPHYLAXIS IN DIFFUSE LARGE B-CELL and/or BCL6 rearrangements (HGBCL-DH/TH).13 Indeed, Bobillo et al. observed that patients with ABC (non-GCB) DLBCL subtype had an overall higher risk of CNS relapse in their series.1Furthermore, recent multiplatform genom- ic profiling studies have identified geneticsubtypes of
INTERNATIONAL RECOMMENDATIONS ON THE DIAGNOSIS AND Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without a previous history of bleeding. Patients typically present with an isolated prolonged activated partial thromboplastin time due to FVIII deficiency. Neutralizing antibodies (inhibitors) are detected using the Nijmegen-modified THE LIFE OF PATIENTS WITH THALASSEMIA MAJOR Figure 1. Survival in 2009 of Italian patients included in the Seven Centers Study, according to birth cohort. The major step forward in improving survival and reducing complications was the introduction, in the 1960s, of the chelating agent deferoxamine, first as an intramuscular injection and later as a subcutaneous infusion. IDENTIFICATION OF A NOVEL ERYTHROID-SPECIFIC ENHANCER FOR Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the NEW PATHOGENIC MECHANISMS INDUCED BY GERMLINE Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause the ELUCIDATING THE SPECTRUM OF Α-THALASSEMIA MUTATIONS IN α thalassemia (α-thal) is one of the most common hemoglobin (Hb) disorders in the world.1 α-globin genes are located on chromosome 16. The majority of α-thal mutations are deletions but point mutations are found as well.2 Since the Iranian population is a mixture of different ethnic groups, frequency and distribution of α-globin mutations in various regions of the country need to be THE COMPLEX KARYOTYPE LANDSCAPE IN CHRONIC LYMPHOCYTIC The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation by Andrea Visentin, Laura Bonaldi, CANDIDATE GENE ASSOCIATION STUDIES AND RISK OF CHILDHOOD To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996–July 2009). Studies had to meet the following criteria: be case-control design, be studied by two or more studies, not be focused on HLA antigen genetic CHROMOSOME 1Q21 ABNORMALITIES REFINE OUTCOME PREDICTION IN 1 Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients Niels Weinhold 1, Hans J. Salwender2, David A Cairns3, Marc S. Raab, George Waldron4, Igor W Blau5, Uta Bertsch1, Thomas Hielscher6, Gareth J Morgan7, Anna Jauch8, Faith E Davies7, Mathias Hänel9, Gordon Cook10, Christoph Scheid11, Richard Houlston4, Hartmut SUPPLEMENTARY APPENDIX SUPPLEMENTARY APPENDIX Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia Hui 1Wei, ,23 Chunlin Zhou,3 Dong Lin,3 Bingcheng 3Liu,3 Yan Li,3 Xingli Zhao,3 Shuning Wei,3 Benfa Gong,3 Kaiqi Liu, Xiaoyuan Gong,3 Yuntao Liu,3 Guangji Zhang,3 Jiayuan Chen,1 Junping Zhang,3 Jingjing Jin,3 Shaowei Qiu,3 Runxia Gu,3 Ying Wang,2,3Yingchang
TIME TO RECONSIDER CD33 SNP FOR GEMTUZUMAB RESPONSE Time to reconsider CD33 SNP for Gemtuzumab response Jatinder K Lamba1 and Soheil Meshinchi2 1Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, UF Health Cancer Center, University of Florida, Gainesville, FL; 2Division of Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance.SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance.SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
EARLY VIEW | HAEMATOLOGICA The COVID-19 pandemic has resulted in significant morbidity and mortality worldwide. To prevent severe infection, mass COVID-19 vaccination campaigns with several vaccine types are currently underway. We report pathological and immunological findings in 8 patients who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after administration of SARS-CoV-2 vaccine ARCHIVES | HAEMATOLOGICA We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. IDENTIFICATION OF A NOVEL ERYTHROID-SPECIFIC ENHANCER FOR Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the NEW PATHOGENIC MECHANISMS INDUCED BY GERMLINE Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause the FAMILIAL MYELODYSPLASTIC SYNDROMES: A REVIEW OF THE Familial cases of myelodysplastic syndromes are rare, but are immensely valuable for the investigation of the molecular pathogenesis of myelodysplasia in general. The best-characterized familial myelodysplastic syndrome is that of familial platelet disorder with propensity to myeloid malignancy, caused by heterozygous germlineRUNX1 mutations.
CHARACTERISTICS AND OUTCOME OF PATIENTS WITH LOW KAYSER et al. Outcome after ATO-based therapy in adult APL INTRODUCTION Acute promyelocytic leukemia (APL), characterized by the balanced translocation t(15;17)(q22;q12) resulting in the fusion transcript PML-RARA, is a rare entity of acute myeloid leukemia (AML), accounting for roughly 5-8% of AML patients.1 With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute ADOPTIVE T-CELL THERAPY FOR MALIGNANT DISORDERS Adoptive cell transfer (ACT) using ex vivo manipulated T lymphocytes has emerged as an important advance in cancer immunotherapy, allowing for re-education and re-setting of the host immune system. Recent technological advances, particularly the development of artificial antigen presenting cells (aAPCs) for ex vivo stimulation and cell expansion that improve upon nature, can re-educate T P2X7 RECEPTOR POLYMORPHISM AND CLINICAL OUTCOMES IN HLA Background and Objectives The P2X7 receptor (P2X7 R) is a key player in the processing and release of interleukin (IL)-1. To evaluate whether the A1513C polymorphism of the P2X7 R gene is related to allogeneic stem cell transplantation outcome, we performed an association analysis between this polymorphism and clinical outcomes in patients treated with an HLA-matched sibling stem cell COMMENT - HAEMATOLOGICA.ORG 1778 haematologica | 2021; 106(6) COMMENT Breast dose matters This high quality meta-analysis by Tromeur et al.1 imparts great additional value to the recent Cochrane DEREGULATION OF APOPTOSIS IN ACUTE MYELOID LEUKEMIA Apoptosis, or programmed cell death, is central to the development and homeostasis of the hematopoietic system. Dysregulation of apoptosis plays an important role in the development of a variety of human pathologies, including cancer, autoimmune diseases and neurodegenerative disorders. Studies carried out in the last years have shown that leukemia cells invariably have abnormalities in one or HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance.SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance.SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
EARLY VIEW | HAEMATOLOGICA The COVID-19 pandemic has resulted in significant morbidity and mortality worldwide. To prevent severe infection, mass COVID-19 vaccination campaigns with several vaccine types are currently underway. We report pathological and immunological findings in 8 patients who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after administration of SARS-CoV-2 vaccine IDENTIFICATION OF A NOVEL ERYTHROID-SPECIFIC ENHANCER FOR Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the ARCHIVES | HAEMATOLOGICA We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. CHARACTERISTICS AND OUTCOME OF PATIENTS WITH LOW KAYSER et al. Outcome after ATO-based therapy in adult APL INTRODUCTION Acute promyelocytic leukemia (APL), characterized by the balanced translocation t(15;17)(q22;q12) resulting in the fusion transcript PML-RARA, is a rare entity of acute myeloid leukemia (AML), accounting for roughly 5-8% of AML patients.1 With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute THE CENTRAL NERVOUS SYSTEM MICROENVIRONMENT INFLUENCES THE Central nervous system (CNS) relapse is a principal cause of treatment failure among patients with acute lymphoblastic leukemia (ALL). Isolated CNS relapse occurs in approximately 3%–8% of children with leukemia and accounts for 30%–40% of initial relapses in some clinical trials.1 Furthermore, CNS-directed therapies are associated with seizures, secondary neoplasms, encephalopathy, and NEW PATHOGENIC MECHANISMS INDUCED BY GERMLINE Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause the CANDIDATE GENE ASSOCIATION STUDIES AND RISK OF CHILDHOOD To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996–July 2009). Studies had to meet the following criteria: be case-control design, be studied by two or more studies, not be focused on HLA antigen genetic ADOPTIVE T-CELL THERAPY FOR MALIGNANT DISORDERS Adoptive cell transfer (ACT) using ex vivo manipulated T lymphocytes has emerged as an important advance in cancer immunotherapy, allowing for re-education and re-setting of the host immune system. Recent technological advances, particularly the development of artificial antigen presenting cells (aAPCs) for ex vivo stimulation and cell expansion that improve upon nature, can re-educate T CHARACTERIZATION OF LEUKEMIAS WITH ETV6-ABL1 FUSION To characterize the incidence, clinical features and genetics of ETV6-ABL1 leukemias, representing targetable kinase-activating lesions, we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies . COMMENT - HAEMATOLOGICA.ORG 1778 haematologica | 2021; 106(6) COMMENT Breast dose matters This high quality meta-analysis by Tromeur et al.1 imparts great additional value to the recent Cochrane HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance.SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
EARLY VIEW | HAEMATOLOGICA The proteasome inhibitors (PIs), carfilzomib and bortezomib, are widely used to treat myeloma but head-to-head comparisons have produced conflicting results. We compared the activity of these PIs in combination with cyclophosphamide and dexamethasone (KCd vs VCd) in second line treatment using fixed duration therapy and evaluated the efficacy of carfilzomib maintenance.SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
EARLY VIEW | HAEMATOLOGICA The COVID-19 pandemic has resulted in significant morbidity and mortality worldwide. To prevent severe infection, mass COVID-19 vaccination campaigns with several vaccine types are currently underway. We report pathological and immunological findings in 8 patients who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after administration of SARS-CoV-2 vaccine IDENTIFICATION OF A NOVEL ERYTHROID-SPECIFIC ENHANCER FOR Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the ARCHIVES | HAEMATOLOGICA We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. CHARACTERISTICS AND OUTCOME OF PATIENTS WITH LOW KAYSER et al. Outcome after ATO-based therapy in adult APL INTRODUCTION Acute promyelocytic leukemia (APL), characterized by the balanced translocation t(15;17)(q22;q12) resulting in the fusion transcript PML-RARA, is a rare entity of acute myeloid leukemia (AML), accounting for roughly 5-8% of AML patients.1 With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute THE CENTRAL NERVOUS SYSTEM MICROENVIRONMENT INFLUENCES THE Central nervous system (CNS) relapse is a principal cause of treatment failure among patients with acute lymphoblastic leukemia (ALL). Isolated CNS relapse occurs in approximately 3%–8% of children with leukemia and accounts for 30%–40% of initial relapses in some clinical trials.1 Furthermore, CNS-directed therapies are associated with seizures, secondary neoplasms, encephalopathy, and NEW PATHOGENIC MECHANISMS INDUCED BY GERMLINE Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause the CANDIDATE GENE ASSOCIATION STUDIES AND RISK OF CHILDHOOD To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996–July 2009). Studies had to meet the following criteria: be case-control design, be studied by two or more studies, not be focused on HLA antigen genetic ADOPTIVE T-CELL THERAPY FOR MALIGNANT DISORDERS Adoptive cell transfer (ACT) using ex vivo manipulated T lymphocytes has emerged as an important advance in cancer immunotherapy, allowing for re-education and re-setting of the host immune system. Recent technological advances, particularly the development of artificial antigen presenting cells (aAPCs) for ex vivo stimulation and cell expansion that improve upon nature, can re-educate T CHARACTERIZATION OF LEUKEMIAS WITH ETV6-ABL1 FUSION To characterize the incidence, clinical features and genetics of ETV6-ABL1 leukemias, representing targetable kinase-activating lesions, we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies . COMMENT - HAEMATOLOGICA.ORG 1778 haematologica | 2021; 106(6) COMMENT Breast dose matters This high quality meta-analysis by Tromeur et al.1 imparts great additional value to the recent Cochrane HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
One of the ALDH family genes, ALDH1A2, is aberrantly expressed in more than 50% of cases of T-cell acute lymphoblastic leukemia. This study revealed that ALDH1A2 protects against intracellular stress and promotes T-ALL cell metabolism and survival. VOL. 106 NO. 6 (2021): JUNE, 2021 Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP (485 Online Views) Ron Daniel Jachimowicz, Luise Pieper, Sarah Reinke, Artur Gontarewicz, Annette Plütschow, Heinz Haverkamp, Leonie Frauenfeld, Falko Fend, Mathis Overkamp, Franziska Jochims HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
THE CLINICAL IMPACT OF PONATINIB ON THE RISK OF BLEEDING We have read with interest the early release paper by Neelakantan et al. regarding platelet dysfunction associated with ponatinib in patients with chronic myeloid leukemia (CML) resistant to multiple tyrosine kinase inhibitors (TKI) therapy.1 The authors have shown a prolonged closure time with PFA 100 (a sensitive measure for primary hemostasis)2 in 5 patients with CML resistant to TKI who HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
One of the ALDH family genes, ALDH1A2, is aberrantly expressed in more than 50% of cases of T-cell acute lymphoblastic leukemia. This study revealed that ALDH1A2 protects against intracellular stress and promotes T-ALL cell metabolism and survival. VOL. 106 NO. 6 (2021): JUNE, 2021 Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP (485 Online Views) Ron Daniel Jachimowicz, Luise Pieper, Sarah Reinke, Artur Gontarewicz, Annette Plütschow, Heinz Haverkamp, Leonie Frauenfeld, Falko Fend, Mathis Overkamp, Franziska Jochims HAEMATOLOGICA ATLAS OF HEMATOLOGIC CYTOLOGY “The Atlas is, of course, very well illustrated..the text is accurate and comprehensive” “Laboratories would benefit from purchasing the printed version and having it on their shelves forready reference.”
SUBMIT A MANUSCRIPT
What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization EFFICACY AND OUTCOME OF AUTOLOGOUS TRANSPLANTATION IN RARESEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
THE CLINICAL IMPACT OF PONATINIB ON THE RISK OF BLEEDING We have read with interest the early release paper by Neelakantan et al. regarding platelet dysfunction associated with ponatinib in patients with chronic myeloid leukemia (CML) resistant to multiple tyrosine kinase inhibitors (TKI) therapy.1 The authors have shown a prolonged closure time with PFA 100 (a sensitive measure for primary hemostasis)2 in 5 patients with CML resistant to TKI who HYPERSENSITIVITY REACTIONS TO INTRAVENOUS IRON: GUIDANCESEE MORE ONHAEMATOLOGICA.ORG
EARLY VIEW | HAEMATOLOGICA The COVID-19 pandemic has resulted in significant morbidity and mortality worldwide. To prevent severe infection, mass COVID-19 vaccination campaigns with several vaccine types are currently underway. We report pathological and immunological findings in 8 patients who developed vaccine-induced immune thrombotic thrombocytopenia (VITT) after administration of SARS-CoV-2 vaccine ARCHIVES | HAEMATOLOGICA We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. IDENTIFICATION OF A NOVEL ERYTHROID-SPECIFIC ENHANCER FOR Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the CHARACTERISTICS AND OUTCOME OF PATIENTS WITH LOW KAYSER et al. Outcome after ATO-based therapy in adult APL INTRODUCTION Acute promyelocytic leukemia (APL), characterized by the balanced translocation t(15;17)(q22;q12) resulting in the fusion transcript PML-RARA, is a rare entity of acute myeloid leukemia (AML), accounting for roughly 5-8% of AML patients.1 With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute NEW PATHOGENIC MECHANISMS INDUCED BY GERMLINE Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause the THE CENTRAL NERVOUS SYSTEM MICROENVIRONMENT INFLUENCES THE Central nervous system (CNS) relapse is a principal cause of treatment failure among patients with acute lymphoblastic leukemia (ALL). Isolated CNS relapse occurs in approximately 3%–8% of children with leukemia and accounts for 30%–40% of initial relapses in some clinical trials.1 Furthermore, CNS-directed therapies are associated with seizures, secondary neoplasms, encephalopathy, and HOSPITALIZATION OF CHILDREN WITH SICKLE CELL DISEASE IN A Sickle cell disease (SCD) has become a paradigm of immigration hematology in Europe. Accurate up-to date information is needed to determine SCD prevalence, define real burden of disease and develop appropriate clinical networks of care, especially in regions lacking screening programs. We used two independent sources of data (Regional Register of Rare Disorders and Regional Register of CANDIDATE GENE ASSOCIATION STUDIES AND RISK OF CHILDHOOD To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996–July 2009). Studies had to meet the following criteria: be case-control design, be studied by two or more studies, not be focused on HLA antigen genetic CHARACTERIZATION OF LEUKEMIAS WITH ETV6-ABL1 FUSION To characterize the incidence, clinical features and genetics of ETV6-ABL1 leukemias, representing targetable kinase-activating lesions, we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies . COMMENT - HAEMATOLOGICA.ORG 1778 haematologica | 2021; 106(6) COMMENT Breast dose matters This high quality meta-analysis by Tromeur et al.1 imparts great additional value to the recent Cochrane HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization MULTIPLE MYELOMA: THE (R)EVOLUTION OF CURRENT THERAPY ANDSEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND 5 Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of thetranscriptional
CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
COMPARATIVE ANALYSIS OF TARGETED NOVEL THERAPIES IN Table 1. Baseline characteristics of each novel therapy cohort. To our knowledge, this is the largest series comparing ibrutinib and venetoclax-based treatment in R/R CLL. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization MULTIPLE MYELOMA: THE (R)EVOLUTION OF CURRENT THERAPY ANDSEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ONHAEMATOLOGICA.ORG
COMPARATIVE ANALYSIS OF TARGETED NOVEL THERAPIES IN Table 1. Baseline characteristics of each novel therapy cohort. To our knowledge, this is the largest series comparing ibrutinib and venetoclax-based treatment in R/R CLL. SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND 5 Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of thetranscriptional
ABOUT THE JOURNAL
About Haematologica. Haematologica publishes articles in the broad field of hematology, reporting on novel important findings in basic, clinical and translational research. Haematologica's bibliometric indicators and positions among hematology journals in 2020 are shown below. The journal is owned by the Ferrata-Storti Foundation(non-profit
CHARACTERISTICS AND OUTCOME OF PATIENTS WITH LOW KAYSER et al. Outcome after ATO-based therapy in adult APL INTRODUCTION Acute promyelocytic leukemia (APL), characterized by the balanced translocation t(15;17)(q22;q12) resulting in the fusion transcript PML-RARA, is a rare entity of acute myeloid leukemia (AML), accounting for roughly 5-8% of AML patients.1 With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute IDENTIFICATION OF A NOVEL ERYTHROID-SPECIFIC ENHANCER FOR Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the NEW PATHOGENIC MECHANISMS INDUCED BY GERMLINE Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause theEDITORIAL TEAM
Carlo Balduini (Pavia), Jerry Radich (Seattle) Managing Director. Antonio Majocchi (Pavia) Associate Editors. Hélène Cavé (Paris), Monika Engelhardt (Freiburg), Steve Lane (Brisbane), Pier Mannuccio Mannucci (Milan), Pavan Reddy (Ann Arbor), David C. Rees (London), Francesco Rodeghiero (Vicenza), Gilles Salles (New York), Kerry Savage ADOPTIVE T-CELL THERAPY FOR MALIGNANT DISORDERS Adoptive cell transfer (ACT) using ex vivo manipulated T lymphocytes has emerged as an important advance in cancer immunotherapy, allowing for re-education and re-setting of the host immune system. Recent technological advances, particularly the development of artificial antigen presenting cells (aAPCs) for ex vivo stimulation and cell expansion that improve upon nature, can re-educate T COMMENT - HAEMATOLOGICA.ORG 1778 haematologica | 2021; 106(6) COMMENT Breast dose matters This high quality meta-analysis by Tromeur et al.1 imparts great additional value to the recent Cochrane ITALIAN SOCIETY OF HEMATOLOGY GUIDELINES FOR THALASSEMIA We greatly appreciated the comments of Dr Nielsen and colleagues on the guidelines for the management of iron overload in thalassemia we produced on behalf of the Italian Society of Hematology.1 Dr Nielsen and colleagues are concerned about our interpretation of data regarding the accuracy of biomagnetic liver susceptometry (BLS) as a non-invasive method for assessing liver iron CHARACTERIZATION OF LEUKEMIAS WITH ETV6-ABL1 FUSION To characterize the incidence, clinical features and genetics of ETV6-ABL1 leukemias, representing targetable kinase-activating lesions, we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies . CANDIDATE GENE ASSOCIATION STUDIES AND RISK OF CHILDHOOD To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996–July 2009). Studies had to meet the following criteria: be case-control design, be studied by two or more studies, not be focused on HLA antigen genetic HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization MULTIPLE MYELOMA: THE (R)EVOLUTION OF CURRENT THERAPY ANDSEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND 5 Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of thetranscriptional
CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ON HAEMATOLOGICA.ORGACQUIRED VON WILLEBRAND AORTIC STENOSISACQUIRED VON WILLEBRAND LVADACQUIRED VON WILLEBRAND UPTODATE COMPARATIVE ANALYSIS OF TARGETED NOVEL THERAPIES IN Table 1. Baseline characteristics of each novel therapy cohort. To our knowledge, this is the largest series comparing ibrutinib and venetoclax-based treatment in R/R CLL. HAEMATOLOGICACURRENT ISSUEEARLY VIEWARCHIVEABOUT USCONTACTSUBMIT AMANUSCRIPT
Although mutations in HAX1 are frequently detected in individuals with severe congenital neutropenia, the role of this gene is poorly understood. This study used a zebrafish model and found that knockdown of hax1 reduces the expression of cebpa and hcls1, two downstream target genes of the granulocyte colony-stimulating factor signalingpathway.
VOL. 106 NO. 6 (2021): JUNE, 2021 TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma (541 Online Views) Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, So Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiro Fujii, Kumiko Kagawa, HirokazuMiki
SUBMIT A MANUSCRIPT
submit menu. What about you? Tell us your interest and get all the new contents of haematologica in advance. VOL. 100 NO. SUPPL_1 (2015): JUNE, 2015 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization MULTIPLE MYELOMA: THE (R)EVOLUTION OF CURRENT THERAPY ANDSEE MORE ONHAEMATOLOGICA.ORG
VOL. 102 NO. S2 (2017): JUNE, 2017 Open access journal of the Ferrata-Storti Foundation, a no profit organization Open access journal of the Ferrata-Storti Foundation, a no profit organization SYNERGISTIC EFFECTS OF PRIMA-1MET (APR-246) AND 5 Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1Met(APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of thetranscriptional
CHROMOSOME Y LOSS AND DRIVERS OF CLONAL HEMATOPOIESIS IN Editorials haematologica | 2021; 106(2) 329 Chromosome Y loss and drivers of clonal hematopoiesis in myelodysplastic syndrome Panagiotis Baliakas1 and Lars A. Forsberg1, 2 1Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University and 2The Beijer Laboratory, Uppsala University, Uppsala, Sweden ACQUIRED VON WILLEBRAND SYNDROME: FOCUSED FORSEE MORE ON HAEMATOLOGICA.ORGACQUIRED VON WILLEBRAND AORTIC STENOSISACQUIRED VON WILLEBRAND LVADACQUIRED VON WILLEBRAND UPTODATE COMPARATIVE ANALYSIS OF TARGETED NOVEL THERAPIES IN Table 1. Baseline characteristics of each novel therapy cohort. To our knowledge, this is the largest series comparing ibrutinib and venetoclax-based treatment in R/R CLL.ABOUT THE JOURNAL
About Haematologica. Haematologica publishes articles in the broad field of hematology, reporting on novel important findings in basic, clinical and translational research. Haematologica's bibliometric indicators and positions among hematology journals in 2020 are shown below. The journal is owned by the Ferrata-Storti Foundation(non-profit
CHARACTERISTICS AND OUTCOME OF PATIENTS WITH LOW KAYSER et al. Outcome after ATO-based therapy in adult APL INTRODUCTION Acute promyelocytic leukemia (APL), characterized by the balanced translocation t(15;17)(q22;q12) resulting in the fusion transcript PML-RARA, is a rare entity of acute myeloid leukemia (AML), accounting for roughly 5-8% of AML patients.1 With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) acute IDENTIFICATION OF A NOVEL ERYTHROID-SPECIFIC ENHANCER FOR Erythroid-specific 5-aminolevulinate synthase (ALAS2) is the rate-limiting enzyme for heme biosynthesis in erythroid cells, and a missense mutation of the ALAS2 gene is associated with congenital sideroblastic anemia. However, the gene responsible for this form of anemia remains unclear in about 40% of patients. Here, we identify a novel erythroid-specific enhancer of 130 base pairs in the NEW PATHOGENIC MECHANISMS INDUCED BY GERMLINE Primary familial and congenital polycythemia is characterized by erythropoietin hypersensitivity of erythroid progenitors due to germline nonsense or frameshift mutations in the erythropoietin receptor gene. All mutations so far described lead to the truncation of the C-terminal receptor sequence that contains negative regulatory domains. Their removal is presented as sufficient to cause theEDITORIAL TEAM
Carlo Balduini (Pavia), Jerry Radich (Seattle) Managing Director. Antonio Majocchi (Pavia) Associate Editors. Hélène Cavé (Paris), Monika Engelhardt (Freiburg), Steve Lane (Brisbane), Pier Mannuccio Mannucci (Milan), Pavan Reddy (Ann Arbor), David C. Rees (London), Francesco Rodeghiero (Vicenza), Gilles Salles (New York), Kerry Savage ADOPTIVE T-CELL THERAPY FOR MALIGNANT DISORDERS Adoptive cell transfer (ACT) using ex vivo manipulated T lymphocytes has emerged as an important advance in cancer immunotherapy, allowing for re-education and re-setting of the host immune system. Recent technological advances, particularly the development of artificial antigen presenting cells (aAPCs) for ex vivo stimulation and cell expansion that improve upon nature, can re-educate T COMMENT - HAEMATOLOGICA.ORG 1778 haematologica | 2021; 106(6) COMMENT Breast dose matters This high quality meta-analysis by Tromeur et al.1 imparts great additional value to the recent Cochrane ITALIAN SOCIETY OF HEMATOLOGY GUIDELINES FOR THALASSEMIA We greatly appreciated the comments of Dr Nielsen and colleagues on the guidelines for the management of iron overload in thalassemia we produced on behalf of the Italian Society of Hematology.1 Dr Nielsen and colleagues are concerned about our interpretation of data regarding the accuracy of biomagnetic liver susceptometry (BLS) as a non-invasive method for assessing liver iron CHARACTERIZATION OF LEUKEMIAS WITH ETV6-ABL1 FUSION To characterize the incidence, clinical features and genetics of ETV6-ABL1 leukemias, representing targetable kinase-activating lesions, we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies . CANDIDATE GENE ASSOCIATION STUDIES AND RISK OF CHILDHOOD To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996–July 2009). Studies had to meet the following criteria: be case-control design, be studied by two or more studies, not be focused on HLA antigen geneticPlease click here
if you are not redirected within a few seconds. Open access journal of the Ferrata-Storti Foundation, a no profitorganization
Open access journal of the Ferrata-Storti Foundation, a no profitorganization
__
* Home
* Current Issue
* Early view
* Archive
* About Us
About Hematologica Editorial TeamOur Policies
* Contact
Advertising Rights &Permissions
* Submit a ManuscriptAuthor Guidelines
Reviewer Guidelines
Submit a manuscript Track aManuscript
* __
Open access journal of the Ferrata-Storti Foundation, a no profitorganization
CURRENT ISSUE
JUNE, 2021
No. 106 (6)
* __ TABLE OF CONTENTS * __ DOWNLOAD THE ISSUE * __ ABOUT THE COVER 2019 Impact Factor: 7.116×
JUNE, 2021
No. 106 (6)
Loading...
Loading...
EDITOR'S PICKS
ARTICLE
RUNX1-EVI1 DISRUPTS LINEAGE DETERMINATION AND THE CELL CYCLE BY INTERFERING WITH RUNX1 AND EVI1 DRIVEN GENE REGULATORY NETWORKS Sophie G. Kellaway et al.ARTICLE
POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS ANTI-THYMOCYTE GLOBULIN FOR GRAFT-VERSUS-HOST DISEASE PREVENTION IN HAPLOIDENTICAL TRANSPLANTATION FOR ADULT ACUTE LYMPHOBLASTIC LEUKEMIAArnon Nagler et al.
ARTICLE
A FREQUENT NONSENSE MUTATION IN EXON 1 ACROSS CERTAIN HLA-A AND -B ALLELES IN LEUKOCYTES OF PATIENTS WITH ACQUIRED APLASTIC ANEMIA Hiroki Mizumaki et al.ARTICLE
MIR-146A IS A PIVOTAL REGULATOR OF NEUTROPHIL EXTRACELLULAR TRAP FORMATION PROMOTING THROMBOSIS Ana B. Arroyo et al.LETTER
SERUM MONOCLONAL COMPONENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: BASELINE CORRELATIONS AND PROGNOSTIC IMPACTPablo Mozas et al.
LETTER
MK2 IS A THERAPEUTIC TARGET FOR HIGH-RISK MULTIPLE MYELOMAChunyan Gu et al.
ARTICLES IN THREE SENTENCESARTICLE
ONCOREQUISITE ROLE OF AN ALDEHYDE DEHYDROGENASE IN THE PATHOGENESIS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA One of the ALDH family genes, ALDH1A2, is aberrantly expressed in more than 50% of cases of T-cell acute lymphoblastic leukemia. This study revealed that ALDH1A2 protects against intracellular stress and promotes T-ALL cell metabolism and survival. ALDH1A2 overexpression enables leukemic clones to sustain a hyper-proliferative state drivenby oncogenes.
Chujing Zhang et al.ARTICLE
NATURAL ESTROGENS ENHANCE THE ENGRAFTMENT OF HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS IN IMMUNODEFICIENT MICE This study found that hematopoietic stem and progenitor cells subsets express estrogen receptors, and that signaling is activated by estradiol and estetrol. Estetrol enhanced human reconstitution in immunodeficient mice directly, by modulating human hematopoietic progenitor properties, and indirectly, by interacting with the bone marrow niche. This might have particular relevance for improving hematopoietic recovery after myeloablative conditioning, especially when limited numbers of HSPC are available. Sara Fañanas-Baquero et al.ARTICLE
BRENTUXIMAB VEDOTIN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-POSITIVE B-CELL LYMPHOMAS A phase I/II multi-center trial used six cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for treatment of CD30-positive B-cell lymphomas. The overall response rate was 100% with 86% of patients achieving complete response. The 2-year progression-free survival and overall survival rates were 85% and 100%. Jakub Svoboda et al.LETTER
THE SURVIVAL IMPACT OF MAINTENANCE LENALIDOMIDE: AN ANALYSIS OF REAL-WORLD DATA FROM THE CANADIAN MYELOMA RESEARCH GROUP NATIONALDATABASE
This is a retrospective, observational study in the realworld of 1,256 patients with myeloma treated with bortezomib-based induction chemotherapy followed by autologous stem cell transplant; 57.6% of patients received lenalidomide maintenance and 42.4% did not. Maintenance had positive impact on response, progression free survival and overall survival. This supports maintenance with lenalidomide as astandard of care.
Hannah M. Cherniawsky et al. TAKE ADVANTAGE FROM HAEMATOLOGICA EASY FIRST SUBMISSION Submit your manuscript without worries: we are flexible at first submission, all formats accepted.LEARN MORE __
GET IMMEDIATE FREE ACCESS TO ALL ISSUESGET NOW __
ACCEPTED MANUSCRIPT PUBLISHED PROMPTLYSUBMIT NOW __
SUBSCRIBE AND GET ETOCS IN ADVANCESUBSCRIBE NOW __
BROWSE THE ATLAS FOR FREE 800 color images, 290 pages, 35 chapters READ ATLAS ONLINE __NAVIGATE
* Home
* Current issue
* Early view
* Archive
* About Haematologica* Editorial Team
* Our policies
FOR AUTHORS
* Author Guidelines
* Submit Manuscript
* Track Manuscript
FOR REVIEWERS
* Reviewer Guidelines * Access Your Profile* Access Your Tasks
FOR ADVERTISERS
* Informations For AdvertisingEDUCATION
* Review Articles
* Guidelines ArticlesPRIVACY
* Cookie Policy
* Newsletter Privacy Policy* Privacy Policy
MORE
* Rights & Permissions* Web design
* Development
Copyright © 2021 by the Ferrata Storti Foundation| Web design →
| Development →
ISSN 0390-6078 print | ISSN 1592-8721 online We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out moreContinue and Accept
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0